Pfizer's third-quarter earnings fell 19% as the drug maker's sales weakened across most of its businesses, particularly its primary care segment.
via WSJ.com: US Business http://online.wsj.com/article/SB10001424052702303471004579165240668917018.html?mod=pls_whats_news_us_business_f
via WSJ.com: US Business http://online.wsj.com/article/SB10001424052702303471004579165240668917018.html?mod=pls_whats_news_us_business_f
Nessun commento:
Posta un commento